Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-09-10

JOHNSON & JOHNSON (JNJ)

CEO Joaquin Duato was paid $32,758,111 in fiscal year 2025, ↑ up 34.8% from fiscal year 2024, the 77th percentile of its disclosed peer group (SEC filing 0000200406-26-000063 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$32,758,111 ↑
Joaquin Duato total, FY2025
77th
CEO pay percentile vs peers
360:1
CEO-to-median pay ratio
94.7%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Joaquin Duato (Chairman/CEO), FY2025 total compensation $32,758,111 (base salary $1,600,000) [exec_comp, SEC accession 0000200406-26-000063, filed 2026-03-11]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

JNJ's next annual pay disclosure, estimated March 10, 2027.est. Filing ↗

Page 2 of 36 of the JOHNSON & JOHNSON Executive Compensation Report, as it is delivered: Executive Summary.

That is page 2 of 36 of the full Executive Compensation Report, shown as it is delivered. The rest:

  1. Summary Compensation Table
  2. Equity transactions since the proxy statement
  3. Grants of plan-based awards
  4. Outstanding equity awards at fiscal year-end
  5. Incentive-plan design (CD&A)
  6. Say-on-pay
  7. CEO pay ratio
  8. Director compensation
  9. Board fee structure and ownership guideline
  10. Disclosed peer group
  11. Source register

Every figure above cites the filing it came from (accession 0000200406-26-000063, filed 2026-09-10) — see the source register, §11.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Joaquin Duato$1,600,000$0$15,028,948$5,927,995$4,298,700$5,301,237$601,231$32,758,111
Chairman/CEO
Joseph Wolk1,240,64606,263,4862,470,5031,860,5602,455,025115,22214,405,442
EVP, CFO
Jennifer Taubert1,220,30806,160,6652,430,0132,002,7502,126,36489,96314,030,063
EVP, WWC Innovative Medicine
John Reed1,220,30806,160,6652,430,0131,810,000458,000135,07612,214,062
EVP, Innovative Medicine, R&D
Tim Schmid942,30803,422,4731,349,9981,507,8002,026,12788,0599,336,765
EVP, WWC, MedTech

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Joaquin Duato$32,758,111$24,302,360$28,397,240↑ +8,455,751
Joseph Wolk14,405,44212,617,56813,914,853↑ +1,787,874
Jennifer Taubert14,030,06311,190,04510,995,394↑ +2,840,018
John Reed12,214,0629,304,43020,647,350↑ +2,909,632
Tim Schmid9,336,76511,862,938—↓ −2,526,173

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read JOHNSON & JOHNSON's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper JNJ reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the JOHNSON & JOHNSON Peer Teardown Report

$32,758,111 Joaquin Duato total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of September 10, 2026 · Source: 0000200406-26-000063 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for JNJ

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
JNJon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order JNJ

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against JNJ
42 companies name JNJ as a compensation peer

Each company listed discloses JNJ in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named JNJ in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Get the JOHNSON & JOHNSON Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Anne M. MulcahyFormer director (through FY2025)$46,952
Daniel E. PintoIndependent Director$62,500
Darius AdamczykFormer director (through FY2025)$64,654
Eugene A. WoodsIndependent Director$347,158
Hubert JolyIndependent Director$367,548
Jennifer A. DoudnaIndependent Director$370,000
John G. MorikisIndependent Director$59,127
Marillyn A. HewsonLead Independent Director$413,000
Mark A. WeinbergerIndependent Director$355,000
Mark B. McClellanIndependent Director$330,000
Mary C. BeckerleIndependent Director$375,000
Nadja Y. WestIndependent Director$350,000
Paula A. JohnsonIndependent Director$344,000
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Dividend-equivalent accruals2026-04-23—12,027——11 insiders, 11 accrual rows
John ReedEVP, Innovative Medicine, R&D2026-05-01D25,25500Derivative, Class A CommonForm 4 ↗
John ReedEVP, Innovative Medicine, R&D2026-05-01A25,25500CommonForm 4 ↗
John ReedEVP, Innovative Medicine, R&D2026-05-01D11,0022302,528,810CommonForm 4 ↗
Marillyn A. HewsonDirector2026-06-09A214.7923350,000Derivative, Class A CommonForm 4 ↗
Daniel E. PintoDirector2026-06-09A134.2423331,250Derivative, Class A CommonForm 4 ↗
Eugene A. WoodsDirector2026-06-09A161.0923337,500Derivative, Class A CommonForm 4 ↗
Kathryn E. WengelEVP, Chief TO and Risk Officer2026-06-11D10,00000Derivative, Class A CommonForm 4 ↗
Kathryn E. WengelEVP, Chief TO and Risk Officer2026-06-11D10,0002412,411,500Common, open-market saleForm 4 ↗
Kathryn E. WengelEVP, Chief TO and Risk Officer2026-06-11A10,0001161,156,700CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20D23,0542515,792,686Common, open-market saleForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20A11,1291301,441,317CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20D11,92500Derivative, Class A CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20D11,12900Derivative, Class A CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20A11,9251321,573,385CommonForm 4 ↗
Joaquin DuatoDirector2026-08-05D6,5232591,687,755Common, open-market saleForm 4 ↗
Joaquin DuatoDirector2026-08-05D41,95725810,827,256Common, open-market saleForm 4 ↗
Elizabeth ForminardEVP, Chief Legal Officer2026-08-06D9,3442582,408,463CommonForm 4 ↗
Elizabeth ForminardEVP, Chief Legal Officer2026-08-06A9,3441321,232,847CommonForm 4 ↗
Elizabeth ForminardEVP, Chief Legal Officer2026-08-06D9,34400Derivative, Class A CommonForm 4 ↗
Elizabeth ForminardEVP, Chief Legal Officer2026-08-06D6,5742561,682,497CommonForm 4 ↗
Joaquin DuatoDirector2026-08-13D20,9762625,495,712CommonForm 4 ↗
Joaquin DuatoDirector2026-08-13A123,29111614,261,070CommonForm 4 ↗
Joaquin DuatoDirector2026-08-13D123,29100Derivative, Class A CommonForm 4 ↗
Joaquin DuatoDirector2026-08-13D102,31526126,704,215CommonForm 4 ↗
Jennifer TaubertEVP, WWC. Innovative Medicine2026-08-17A15,0001161,735,050CommonForm 4 ↗
Jennifer TaubertEVP, WWC. Innovative Medicine2026-08-17D15,00000Derivative, Class A CommonForm 4 ↗
Jennifer TaubertEVP, WWC. Innovative Medicine2026-08-17D15,0002633,950,400Common, open-market saleForm 4 ↗
Tim SchmidEVP, WW Chair, MedTech2026-09-02D22,52700Derivative, Class A CommonForm 4 ↗
Tim SchmidEVP, WW Chair, MedTech2026-09-02A11,0701321,460,576CommonForm 4 ↗
Tim SchmidEVP, WW Chair, MedTech2026-09-02D11,07000Derivative, Class A CommonForm 4 ↗
Tim SchmidEVP, WW Chair, MedTech2026-09-02D22,5272756,189,068CommonForm 4 ↗
Tim SchmidEVP, WW Chair, MedTech2026-09-02A22,5271513,410,813CommonForm 4 ↗
Tim SchmidEVP, WW Chair, MedTech2026-09-02D11,0702753,041,372CommonForm 4 ↗
Eugene A. WoodsDirector2026-09-08A135.7227637,500Derivative, Class A CommonForm 4 ↗
Daniel E. PintoDirector2026-09-08A113.127631,250Derivative, Class A CommonForm 4 ↗
Marillyn A. HewsonDirector2026-09-08A180.9627650,000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 47 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Mary C. BeckerleDirector2026-04-23A975$0$0Derivative, Class A CommonForm 4 ↗
Jennifer A. DoudnaDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
Marillyn A. HewsonDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
Paula A. JohnsonDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
Hubert JolyDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
Mark B. McClellanDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
John G. MorikisDirector2026-04-23A1,54000Derivative, Class A CommonForm 4 ↗
Daniel E. PintoDirector2026-04-23A1,71200Derivative, Class A CommonForm 4 ↗
Mark A. WeinbergerDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
Nadja Y. WestDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
Eugene A. WoodsDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
John ReedEVP, Innovative Medicine, R&D2026-05-01D25,25500Derivative, Class A CommonForm 4 ↗
John ReedEVP, Innovative Medicine, R&D2026-05-01A25,25500CommonForm 4 ↗
John ReedEVP, Innovative Medicine, R&D2026-05-01D11,0022302,528,810CommonForm 4 ↗
Marillyn A. HewsonDirector2026-06-09A214.7923350,000Derivative, Class A CommonForm 4 ↗
Daniel E. PintoDirector2026-06-09A134.2423331,250Derivative, Class A CommonForm 4 ↗
Eugene A. WoodsDirector2026-06-09A161.0923337,500Derivative, Class A CommonForm 4 ↗
Kathryn E. WengelEVP, Chief TO and Risk Officer2026-06-11D10,00000Derivative, Class A CommonForm 4 ↗
Kathryn E. WengelEVP, Chief TO and Risk Officer2026-06-11D10,0002412,411,500Common, open-market saleForm 4 ↗
Kathryn E. WengelEVP, Chief TO and Risk Officer2026-06-11A10,0001161,156,700CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20D23,0542515,792,686Common, open-market saleForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20A11,1291301,441,317CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20D11,92500Derivative, Class A CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20D11,12900Derivative, Class A CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20A11,9251321,573,385CommonForm 4 ↗
Joaquin DuatoDirector2026-08-05D6,5232591,687,755Common, open-market saleForm 4 ↗
Joaquin DuatoDirector2026-08-05D41,95725810,827,256Common, open-market saleForm 4 ↗
Elizabeth ForminardEVP, Chief Legal Officer2026-08-06D9,3442582,408,463CommonForm 4 ↗
Elizabeth ForminardEVP, Chief Legal Officer2026-08-06A9,3441321,232,847CommonForm 4 ↗
Elizabeth ForminardEVP, Chief Legal Officer2026-08-06D9,34400Derivative, Class A CommonForm 4 ↗
Elizabeth ForminardEVP, Chief Legal Officer2026-08-06D6,5742561,682,497CommonForm 4 ↗
Joaquin DuatoDirector2026-08-13D20,9762625,495,712CommonForm 4 ↗
Joaquin DuatoDirector2026-08-13A123,29111614,261,070CommonForm 4 ↗
Joaquin DuatoDirector2026-08-13D123,29100Derivative, Class A CommonForm 4 ↗
Joaquin DuatoDirector2026-08-13D102,31526126,704,215CommonForm 4 ↗
Jennifer TaubertEVP, WWC. Innovative Medicine2026-08-17A15,0001161,735,050CommonForm 4 ↗
Jennifer TaubertEVP, WWC. Innovative Medicine2026-08-17D15,00000Derivative, Class A CommonForm 4 ↗
Jennifer TaubertEVP, WWC. Innovative Medicine2026-08-17D15,0002633,950,400Common, open-market saleForm 4 ↗
Tim SchmidEVP, WW Chair, MedTech2026-09-02D22,52700Derivative, Class A CommonForm 4 ↗
Tim SchmidEVP, WW Chair, MedTech2026-09-02A11,0701321,460,576CommonForm 4 ↗
Tim SchmidEVP, WW Chair, MedTech2026-09-02D11,07000Derivative, Class A CommonForm 4 ↗
Tim SchmidEVP, WW Chair, MedTech2026-09-02D22,5272756,189,068CommonForm 4 ↗
Tim SchmidEVP, WW Chair, MedTech2026-09-02A22,5271513,410,813CommonForm 4 ↗
Tim SchmidEVP, WW Chair, MedTech2026-09-02D11,0702753,041,372CommonForm 4 ↗
Eugene A. WoodsDirector2026-09-08A135.7227637,500Derivative, Class A CommonForm 4 ↗
Daniel E. PintoDirector2026-09-08A113.127631,250Derivative, Class A CommonForm 4 ↗
Marillyn A. HewsonDirector2026-09-08A180.9627650,000Derivative, Class A CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Tim SchmidOPTION2025-02-15——49,878—$1,349,998
Jennifer TaubertRSU2025-02-15——5,539—809,968
Joseph WolkRSU2025-02-15——5,632—823,567
Tim SchmidRSU2025-02-15——3,077—449,950
Joaquin DuatoOPTION2025-02-15——219,020—5,927,995
Joaquin DuatoRSU2025-02-15——13,513—1,976,006
Joseph WolkOPTION2025-02-15——91,277—2,470,503
John ReedRSU2025-02-15——5,539—809,968
Jennifer TaubertOPTION2025-02-15——89,781—2,430,013
Joaquin DuatoPSU2025-02-15083,828—167,65613,052,942
John ReedPSU2025-02-15034,363—68,7265,350,697
Joseph WolkPSU2025-02-15034,936—69,8725,439,919
Jennifer TaubertPSU2025-02-15034,363—68,7265,350,697
Tim SchmidPSU2025-02-15019,090—38,1802,972,523
John ReedOPTION2025-02-15——89,781—2,430,013
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Tim Schmid$449,950$2,972,523$1,349,99862.3%
Jennifer Taubert809,9685,350,6972,430,01362.3%
Joseph Wolk823,5675,439,9192,470,50362.3%
Joaquin Duato1,976,00613,052,9425,927,99562.3%
John Reed809,9685,350,6972,430,01362.3%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Joaquin DuatoOption133,516151.41—
Joaquin DuatoOption110,868131.94—
Jennifer TaubertOption91,324151.41—
Joaquin DuatoOption118,544157.92—
Joseph WolkOption91,277156.15—
Jennifer TaubertOption89,781156.15—
Jennifer TaubertOption82,127164.62—
Jennifer TaubertOption43,391129.51—
Tim SchmidOption22,527151.41—
John ReedOption43,442157.92—
Tim SchmidOption17,431165.89—
Tim SchmidOption8,998129.51—
Tim SchmidOption4,129162.75—
Joaquin DuatoRSU131,652—27,334,905
Joaquin DuatoOption219,020156.15—
Joaquin DuatoOption123,291115.67—
Jennifer TaubertRSU53,968—11,205,376
Joaquin DuatoRSU83,906—17,421,403
Joaquin DuatoOption105,307129.51—
Joaquin DuatoRSU73,053—15,167,994
Jennifer TaubertOption43,712115.67—
Joaquin DuatoOption114,776164.62—
Joseph WolkRSU54,867—11,392,035
John ReedRSU53,968—11,205,376
Joseph WolkRSU44,920—9,326,740
Joseph WolkOption88,219151.41—
Jennifer TaubertOption67,397131.94—
Joaquin DuatoOption99,811165.89—
Joseph WolkOption79,280165.89—
John ReedOption89,781156.15—
Joseph WolkOption66,386131.94—
Joseph WolkOption63,464157.92—
Joseph WolkOption80,976164.62—
Jennifer TaubertOption80,055165.89—
John ReedRSU30,749—6,384,415
Joseph WolkRSU37,463—7,778,443
Jennifer TaubertRSU36,325—7,542,160
Tim SchmidRSU29,981—6,224,955
Joaquin DuatoOption57,416162.75—
Tim SchmidOption49,878156.15—
Jennifer TaubertRSU27,412—5,691,554
Jennifer TaubertOption51,320157.92—
John ReedRSU25,255—5,243,696
Tim SchmidRSU23,432—4,865,186
Tim SchmidOption33,105157.92—
Joseph WolkOption29,444162.75—
Joseph WolkOption19,241115.67—
Joaquin DuatoRSU13,513—2,805,704
Jennifer TaubertOption21,544162.75—
Tim SchmidOption15,571101.87—
Tim SchmidOption21,574164.62—
Tim SchmidOption13,625115.67—
Joaquin DuatoRSU7,364—1,528,987
Joseph WolkOption12,066129.51—
Tim SchmidOption11,070131.94—
Joseph WolkRSU5,632—1,169,372
Jennifer TaubertRSU5,539—1,150,063
John ReedRSU5,539—1,150,063
Tim SchmidRSU4,378—909,004
Joseph WolkRSU3,942—818,477
Joaquin DuatoRSU3,469—720,268
Jennifer TaubertRSU3,188—661,924
Tim SchmidRSU3,077—638,878
John ReedRSU2,698—560,186
Tim SchmidRSU2,056—426,887
Tim SchmidRSU499—103,607
Joseph WolkRSU1,779—369,374
Jennifer TaubertRSU1,302—270,334
05

Incentive-plan design — the Compensation Discussion & Analysis

The Company's compensation program is designed to attract, retain, and motivate leaders, aligning pay with performance and shareholder value.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantSemler Brossy Consulting Group
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-04-231,641,173,03291,774,9239,607,17494.7%Passed
20252025-04-241,559,332,581142,483,9007,360,00991.63%Passed
20242024-04-251,511,199,544159,356,3739,366,86690.46%Passed
20232023-04-271,685,320,654123,275,64711,076,73093.18%Passed
20222022-04-281,579,815,895257,738,12811,483,56885.97%Passed
20212021-04-22986,844,148753,486,15290,895,69356.7%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-04-2394.7%a
20252025-04-2491.63%b
20242024-04-2590.46%c

a. Approved under the standard stated in the filing — “For purposes of determining the number of votes cast with respect to these matters, only those cast "For" or "Against" are included; abstentions and broker non-votes are counted only for purposes of determining whether a quorum is present at the Annual Meeting.”.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)360 : 1
CEO total compensation$32,784,511
Median employee compensation$91,000
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Marillyn A. HewsonIndependent · Lead Independent Director · Compensation & Benefits · Nominating & Corporate Governance (Chair) · Special Committee - Orthopaedics Separation (Chair)$200,000$205,000——$8,000$413,000
Mary C. BeckerleIndependent · Regulatory Compliance & Sustainability · Science & Technology (Chair)150,000205,000——20,000375,000
Jennifer A. DoudnaIndependent · Nominating & Corporate Governance · Science & Technology125,000205,000——40,000370,000
Hubert JolyIndependent · Audit (Chair) · Nominating & Corporate Governance · Special Committee - Orthopaedics Separation142,548205,000——20,000367,548
Mark A. WeinbergerIndependent · Audit · Regulatory Compliance & Sustainability (Chair) · Special Committee - Orthopaedics Separation150,000205,000——0355,000
Nadja Y. WestIndependent · Regulatory Compliance & Sustainability · Science & Technology · Special Committee - Orthopaedics Separation125,000205,000——20,000350,000
Eugene A. WoodsIndependent · Compensation & Benefits (Chair) · Regulatory Compliance & Sustainability142,158205,000——0347,158
Paula A. JohnsonIndependent · Nominating & Corporate Governance · Science & Technology125,000205,000——14,000344,000
Mark B. McClellanIndependent · Regulatory Compliance & Sustainability · Science & Technology125,000205,000——0330,000
Darius AdamczykIndependent · Audit (Chair) · Departed during FY64,6540——064,654
Daniel E. PintoIndependent · Audit · Compensation & Benefits · Special Committee - Orthopaedics Separation · Partial-year service · Newly elected62,5000——062,500
John G. MorikisIndependent · Audit · Compensation & Benefits · Partial-year service · Newly elected39,1270——20,00059,127
Anne M. MulcahyIndependent · Nominating/Governance (Chair) · Departed during FY46,9520——046,952
Joaquin DuatoEmployee director · Board Chair · Finance—————0
09

Board fee structure and ownership guideline

Annual cash retainer$125,000
Annual equity retainer$220,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)30,000 / 25,000 / 25,000
Stock ownership guideline5x annual cash retainer
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$1,497,939
Equity awards (grant-date value)$1,845,000
All other compensation$142,000
Total cost of the board$3,484,939

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies JOHNSON & JOHNSON names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including JOHNSON & JOHNSON.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Microsoft Corporation (MSFT)(9)2025Satya Nadella$2,500,000$84,245,496$0$9,555,000$96,496,790
2Intel Corporation2025Lip-Bu Tan746,20049,639,50039,523,2002,374,00092,990,900
3Eli Lilly and Company2025David Ricks1,700,00023,325,00006,485,50036,698,337
4JOHNSON & JOHNSON2025Joaquin Duato1,600,00015,028,9485,927,9954,298,70032,758,111
5Abbvie Inc.2025Robert Michael1,700,00013,268,4563,199,1545,200,00032,530,984
6AT T Inc.2025John Stankey2,400,00019,500,01206,272,00029,906,872
7Pfizer Inc.2025Albert Bourla1,800,0009,442,7058,998,1415,400,00027,585,301
8RTX Corporation2025Christopher Calio1,525,00010,875,3916,753,909024,846,826
9Amgen Inc.2025Robert Bradway1,925,40912,599,5895,399,9963,907,00024,693,120
10Abbott Laboratories2025Robert Ford1,500,0008,787,3788,788,4301,968,75024,198,660
11The Boeing Company2025Robert Ortberg1,500,0007,874,8189,624,9593,930,00023,581,389
12Medtronic plc2026Geoffrey Martha1,399,03913,672,2005,175,5592,307,20022,940,252
13Bristol Myers Squibb Company2025Christopher Boerner1,586,34616,061,39903,754,68421,879,919
14Merck Co., Inc.2025Robert Davis1,645,30212,102,8383,380,0042,326,50020,797,845

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
JOHNSON & JOHNSONnot disclosednot disclosedYes — Relative TSRSemler Brossy Consulting Group
Abbott Laboratories75.0%Options 50 · PSU 50NoMeridian Compensation Partners, LLC
Abbvie Inc.not disclosedPSU 40 · PRSU 40 · Option 20Yes — Relative TSRSemler Brossy
Amgen Inc.136.0%PSU 50 · Options 30 · RSU 20Yes — relative TSRFrederic W. Cook & Co., Inc. (FW Cook)
AT T Inc.112%PSU 75 · RSU 25Yes — Relative Total Stockholder Return (TSR) Payout ModifierFrederic W. Cook & Co., Inc. (FW Cook)
Bristol Myers Squibb Company157.66%PSU 60 · MSU 40Yes — 3-Year Relative TSR CAGRFarient Advisors LLC
Eli Lilly and Company218%PSU 100NoFW Cook
Intel Corporationnot disclosedPSU 50 · RSU 50 · Option 40Yes — Relative TSRSemler Brossy
Medtronic plc103%PSU 50 · Options 30 · RSU 20NoSemler Brossy
Merck Co., Inc.94%PSU 60 · RSU 20 · Options 20Yes — Relative Total Shareholder Return (R-TSR)FW Cook
Microsoft Corporation (MSFT)(9)not disclosedPSA 100NoPay Governance LLC
Pfizer Inc.150%PSU 50 · MSU 50Yes — relative TSR as compared to the NYSE Arca Pharmaceutical Index (DRG Index or DRG)Meridian Compensation Partners, LLC
RTX Corporation164%PSU 60 · Options 40Yes — TSR vs. Core A&D PeersFW Cook
The Boeing Company131%Options 55 · RSU 45NoFW Cook (Frederic W. Cook & Co., Inc.)

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at JOHNSON & JOHNSON in fiscal 2025?
As disclosed, Joaquin Duato (Chairman/CEO) was the highest-paid executive at JOHNSON & JOHNSON in fiscal 2025, with total compensation of $32,758,111.
How does JOHNSON & JOHNSON's chief executive pay compare to its disclosed peer group?
As disclosed, Joaquin Duato's total compensation ranked at the 77th percentile of JOHNSON & JOHNSON's disclosed peer group.
What is JOHNSON & JOHNSON's CEO-to-median employee pay ratio?
As disclosed, JOHNSON & JOHNSON's CEO-to-median employee pay ratio was 360:1.
How did shareholders vote on JOHNSON & JOHNSON's executive compensation?
As disclosed, 94.7% of shareholders supported JOHNSON & JOHNSON's executive compensation in the latest say-on-pay vote.
How much does JOHNSON & JOHNSON spend in total on board compensation for fiscal 2025?
As disclosed, JOHNSON & JOHNSON reported total board compensation of $3,484,939 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Joaquin DuatoDEF 14A2026-03-110000200406-26-000063Section “summary compensation table”. As printed: 32,758,111. Filing ↗machine: r3 · c27 · span 1621235–1621246
2Section 01, Joseph WolkDEF 14A2026-03-110000200406-26-000063Section “summary compensation table”. As printed: 14,405,442. Filing ↗machine: r6 · c27 · span 1630843–1630853
3Section 01, Jennifer TaubertDEF 14A2026-03-110000200406-26-000063Section “summary compensation table”. As printed: 14,030,063. Filing ↗machine: r9 · c27 · span 1640403–1640413
4Section 01, John ReedDEF 14A2026-03-110000200406-26-000063Section “summary compensation table”. As printed: 12,214,062. Filing ↗machine: r12 · c27 · span 1649964–1649974
5Section 01, Tim SchmidDEF 14A2026-03-110000200406-26-000063Section “summary compensation table”. As printed: 9,336,765. Filing ↗machine: r15 · c27 · span 1659503–1659512
6Section 03, Tim Schmid OPTIONDEF 14A1900-01-010000200406-26-000063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1882397–1882406
7Section 03, Jennifer Taubert RSUDEF 14A1900-01-010000200406-26-000063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
8Section 03, Joseph Wolk RSUDEF 14A1900-01-010000200406-26-000063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1844746–1844753
9Section 03, Tim Schmid RSUDEF 14A1900-01-010000200406-26-000063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1877341–1877348
10Section 03, Joaquin Duato OPTIONDEF 14A1900-01-010000200406-26-000063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
11Section 03, Joaquin Duato RSUDEF 14A1900-01-010000200406-26-000063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1833882–1833891
12Section 03, Joseph Wolk OPTIONDEF 14A1900-01-010000200406-26-000063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1848743–1848752
13Section 03, John Reed RSUDEF 14A1900-01-010000200406-26-000063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
14Section 03, Jennifer Taubert OPTIONDEF 14A1900-01-010000200406-26-000063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1859614–1859623
15Section 03, Joaquin Duato PSUDEF 14A1900-01-010000200406-26-000063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1831886–1831897
16Section 03, John Reed PSUDEF 14A1900-01-010000200406-26-000063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
17Section 03, Joseph Wolk PSUDEF 14A1900-01-010000200406-26-000063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
18Section 03, Jennifer Taubert PSUDEF 14A1900-01-010000200406-26-000063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
19Section 03, Tim Schmid PSUDEF 14A1900-01-010000200406-26-000063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
20Section 03, John Reed OPTIONDEF 14A1900-01-010000200406-26-000063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1870475–1870484
21Section 07, pay ratioDEF 14A2026-03-110000200406-26-000063Section “CEO Pay Ratio”. As printed: 360 : 1. Filing ↗machine: span 2348958–2348966
22Section 08, Marillyn A. HewsonDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 413,000. Filing ↗machine: span 931144–931456
23Section 08, Mary C. BeckerleDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 375,000. Filing ↗machine: span 926943–927255
24Section 08, Jennifer A. DoudnaDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 370,000. Filing ↗machine: span 928955–929267
25Section 08, Hubert JolyDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 367,548. Filing ↗machine: span 935339–935651
26Section 08, Mark A. WeinbergerDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 355,000. Filing ↗machine: span 945735–946047
27Section 08, Nadja Y. WestDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 350,000. Filing ↗machine: span 947745–948057
28Section 08, Eugene A. WoodsDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 347,158. Filing ↗machine: span 950278–950654
29Section 08, Paula A. JohnsonDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 344,000. Filing ↗machine: span 933157–933469
30Section 08, Mark B. McClellanDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 330,000. Filing ↗machine: span 937349–937661
31Section 08, Darius AdamczykDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 64,654. Filing ↗machine: span 924761–925069
32Section 08, Daniel E. PintoDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 62,500. Filing ↗machine: span 942297–942608
33Section 08, John G. MorikisDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 59,127. Filing ↗machine: span 939366–939677
34Section 08, Anne M. MulcahyDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 46,952. Filing ↗machine: span 941541–941852
35Section 08, Joaquin DuatoDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 0. Filing ↗
36Section 02, Mary C. Beckerle 2026-04-23Form 42026-04-270000200406-26-000092Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Jennifer A. Doudna 2026-04-23Form 42026-04-270000200406-26-000094Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Marillyn A. Hewson 2026-04-23Form 42026-04-270000200406-26-000096Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Paula A. Johnson 2026-04-23Form 42026-04-270000200406-26-000098Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Hubert Joly 2026-04-23Form 42026-04-270000200406-26-000100Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Mark B. McClellan 2026-04-23Form 42026-04-270000200406-26-000102Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, John G. Morikis 2026-04-23Form 42026-04-270000200406-26-000104Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Daniel E. Pinto 2026-04-23Form 42026-04-270000200406-26-000106Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Mark A. Weinberger 2026-04-23Form 42026-04-270000200406-26-000108Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Nadja Y. West 2026-04-23Form 42026-04-270000200406-26-000111Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Eugene A. Woods 2026-04-23Form 42026-04-270000200406-26-000113Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, John Reed 2026-05-01Form 42026-05-040000200406-26-000115Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, John Reed 2026-05-01Form 42026-05-040000200406-26-000115Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, John Reed 2026-05-01Form 42026-05-040000200406-26-000115Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Marillyn A. Hewson 2026-06-09Form 42026-06-110000200406-26-000121Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Daniel E. Pinto 2026-06-09Form 42026-06-110000200406-26-000123Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Eugene A. Woods 2026-06-09Form 42026-06-110000200406-26-000125Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Kathryn E. Wengel 2026-06-11Form 42026-06-120000200406-26-000127Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Kathryn E. Wengel 2026-06-11Form 42026-06-120000200406-26-000127Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Kathryn E. Wengel 2026-06-11Form 42026-06-120000200406-26-000127Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Vanessa Broadhurst 2026-07-20Form 42026-07-210000200406-26-000148Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Vanessa Broadhurst 2026-07-20Form 42026-07-210000200406-26-000148Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Vanessa Broadhurst 2026-07-20Form 42026-07-210000200406-26-000148Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Vanessa Broadhurst 2026-07-20Form 42026-07-210000200406-26-000148Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Vanessa Broadhurst 2026-07-20Form 42026-07-210000200406-26-000148Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Joaquin Duato 2026-08-05Form 42026-08-070000200406-26-000171Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Joaquin Duato 2026-08-05Form 42026-08-070000200406-26-000171Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Elizabeth Forminard 2026-08-06Form 42026-08-070000200406-26-000169Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Elizabeth Forminard 2026-08-06Form 42026-08-070000200406-26-000169Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Elizabeth Forminard 2026-08-06Form 42026-08-070000200406-26-000169Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Elizabeth Forminard 2026-08-06Form 42026-08-070000200406-26-000169Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Joaquin Duato 2026-08-13Form 42026-08-140000200406-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Joaquin Duato 2026-08-13Form 42026-08-140000200406-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Joaquin Duato 2026-08-13Form 42026-08-140000200406-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Joaquin Duato 2026-08-13Form 42026-08-140000200406-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Jennifer Taubert 2026-08-17Form 42026-08-180000200406-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Jennifer Taubert 2026-08-17Form 42026-08-180000200406-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Jennifer Taubert 2026-08-17Form 42026-08-180000200406-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Tim Schmid 2026-09-02Form 42026-09-040000200406-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Tim Schmid 2026-09-02Form 42026-09-040000200406-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Tim Schmid 2026-09-02Form 42026-09-040000200406-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Tim Schmid 2026-09-02Form 42026-09-040000200406-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Tim Schmid 2026-09-02Form 42026-09-040000200406-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Tim Schmid 2026-09-02Form 42026-09-040000200406-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Eugene A. Woods 2026-09-08Form 42026-09-100000200406-26-000184Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Daniel E. Pinto 2026-09-08Form 42026-09-100000200406-26-000185Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Marillyn A. Hewson 2026-09-08Form 42026-09-100000200406-26-000183Insider equity transaction reported since the proxy statement. Filing ↗
83Section 06, 2026 voteForm 8-K2026-04-280000200406-26-000089Item 5.07 · say-on-pay result. As reported: 94.7% (votes for as printed: 1,641,173,032). Filing ↗
84Section 06, 2025 voteForm 8-K2025-04-300000200406-25-000141Item 5.07 · say-on-pay result. As reported: 91.63% (votes for as printed: 1,559,332,581). Filing ↗
85Section 06, 2024 voteForm 8-K2024-04-290000200406-24-000043Item 5.07 · say-on-pay result. As reported: 90.46% (votes for as printed: 1,511,199,544.00). Filing ↗
86Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
87Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
88Section 09b board cost (computed)Computed——Cash 1,497,939 + equity 1,845,000 + all other 142,000 = 3,484,939, summed across the director compensation table rows.machine: formula: Σ = 3,484,939
89Microsoft Corporation (MSFT)(9), Section 10b CEO totalDEF 14A2025-10-210001193125-25-245150CEO total compensation as printed in Microsoft Corporation (MSFT)(9)'s own proxy. As printed: 96,496,790. Filing ↗machine: r2 · c27 · span 1059364–1059374
90Intel Corporation, Section 10b CEO totalDEF 14A2026-03-240000050863-26-000066CEO total compensation as printed in Intel Corporation's own proxy. As printed: 92,990,900. Filing ↗machine: r2 · c24 · span 1611286–1611296
91Eli Lilly and Company, Section 10b CEO totalDEF 14A2026-03-200000059478-26-000029CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. Filing ↗machine: t92 · r2 · c20 · span 925013–925024
92JOHNSON & JOHNSON (subject), Section 10b CEO totalDEF 14A2026-03-110000200406-26-000063CEO total compensation as printed in JOHNSON & JOHNSON's own proxy. As printed: 32,758,111. Filing ↗machine: r3 · c27 · span 1621235–1621246
93Abbvie Inc., Section 10b CEO totalDEF 14A2026-03-230001104659-26-033387CEO total compensation as printed in Abbvie Inc.'s own proxy. As printed: 32,530,984. Filing ↗
94AT T Inc., Section 10b CEO totalDEF 14A2026-03-230001193125-26-119888CEO total compensation as printed in AT T Inc.'s own proxy. As printed: 29,906,872. Filing ↗machine: r3 · c35 · span 1189292–1189302
95Pfizer Inc., Section 10b CEO totalDEF 14A2026-03-120000078003-26-000033CEO total compensation as printed in Pfizer Inc.'s own proxy. As printed: 27,585,301. Filing ↗machine: t242 · r3 · c12 · span 1506825–1506835
96RTX Corporation, Section 10b CEO totalDEF 14A2026-03-090001308179-26-000036CEO total compensation as printed in RTX Corporation's own proxy. As printed: 24,846,826. Filing ↗machine: t237 · r2 · c14 · span 908955–908966
97Amgen Inc., Section 10b CEO totalDEF 14A2026-04-070001193125-26-145588CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166
98Abbott Laboratories, Section 10b CEO totalDEF 14A2026-03-130001308179-26-000064CEO total compensation as printed in Abbott Laboratories's own proxy. As printed: 24,198,660. Filing ↗machine: span 1245488–1245498
99The Boeing Company, Section 10b CEO totalDEF 14A2026-03-060001193125-26-096787CEO total compensation as printed in The Boeing Company's own proxy. As printed: 23,581,389. Filing ↗machine: r2 · c44 · span 1170571–1170581
100Medtronic plc, Section 10b CEO totalDEF 14A2026-08-170001613103-26-000010CEO total compensation as printed in Medtronic plc's own proxy. As printed: 22,940,252. Filing ↗machine: span 988220–988230
101Bristol Myers Squibb Company, Section 10b CEO totalDEF 14A2026-03-250000014272-26-000006CEO total compensation as printed in Bristol Myers Squibb Company's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170
102Merck Co., Inc., Section 10b CEO totalDEF 14A2026-04-080001193125-26-147704CEO total compensation as printed in Merck Co., Inc.'s own proxy. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022
103Section 10a, Abbvie Inc. reciprocityDEF 14A—0001104659-26-033387Abbvie Inc. names JOHNSON & JOHNSON in its own disclosed peer group (read from its most recent proxy). Filing ↗
104Section 10a, The Boeing Company reciprocityDEF 14A—0001193125-26-096787The Boeing Company names JOHNSON & JOHNSON in its own disclosed peer group (read from its most recent proxy). Filing ↗
105Section 10a, Eli Lilly and Company reciprocityDEF 14A—0000059478-26-000029Eli Lilly and Company names JOHNSON & JOHNSON in its own disclosed peer group (read from its most recent proxy). Filing ↗
106Section 10a, Amgen Inc. reciprocityDEF 14A—0001193125-26-145588Amgen Inc. names JOHNSON & JOHNSON in its own disclosed peer group (read from its most recent proxy). Filing ↗
107Section 10a, AT T Inc. reciprocityDEF 14A—0001193125-26-119888AT T Inc.'s most recent proxy was read; its disclosed peer group does not include JOHNSON & JOHNSON. Filing ↗
108Section 10a, Bristol Myers Squibb Company reciprocityDEF 14A—0000014272-26-000006Bristol Myers Squibb Company names JOHNSON & JOHNSON in its own disclosed peer group (read from its most recent proxy). Filing ↗
109Section 10a, Intel Corporation reciprocityDEF 14A—0000050863-26-000066Intel Corporation's most recent proxy was read; its disclosed peer group does not include JOHNSON & JOHNSON. Filing ↗
110Section 10a, Merck Co., Inc. reciprocityDEF 14A—0001193125-26-147704Merck Co., Inc. names JOHNSON & JOHNSON in its own disclosed peer group (read from its most recent proxy). Filing ↗
111Section 10a, Microsoft Corporation (MSFT)(9) reciprocityDEF 14A—0001193125-25-245150Microsoft Corporation (MSFT)(9) names JOHNSON & JOHNSON in its own disclosed peer group (read from its most recent proxy). Filing ↗
112Section 10a, Pfizer Inc. reciprocityDEF 14A—0000078003-26-000033Pfizer Inc. names JOHNSON & JOHNSON in its own disclosed peer group (read from its most recent proxy). Filing ↗
113Section 10a, RTX Corporation reciprocityDEF 14A—0001308179-26-000036RTX Corporation's most recent proxy was read; its disclosed peer group does not include JOHNSON & JOHNSON. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the JOHNSON & JOHNSON Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
JNJ Peer Teardown Report